Skip to main content

Table 1 Pharmacodynamic parameters based on anti-Xa measurements * after single-dose subcutaneous administration in 12 healthy volunteers

From: Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

  Average MW Dose AUCa t½ a Clearancea,b
(Da) (IU) (h · IU/mL) (h) (mL/min)
Enoxaparin 4,400 4,000 3.47 ± 0.69 4.28 ± 1.06 19.2
Dalteparin 5,700 5,000 3.17 ± 0.82 2.31 ± 0.60 26.3
3.23 ± 0.85 2.45 ± 0.66 25.8
Tinzaparin 6,500 3,000 1.35 ± 0.39 2.97 ± 1.01 37.0
UFH 12,000–15,000 5,000 1.33 ± 0.70 62.7
  1. aTwo values are reported for dalteparin since the dosing was repeated to give a measure of the intra-individual variation; bCl/F (clearance relative to bioavailability), calculated from data in the publication.
  2. *Clinical data were extracted from Eriksson et al 1995 [35] and compiled specifically for this review (MW data from Schroeder et al 2011 [31]).